Clinical Trial Update: Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial of pembrolizumab added to standard-of-care chemotherapy for triple-negative breast cancer has posted results; the study remains active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Providence Health & Services | Conditions: Triple Negative Breast Cancer | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-02-22